<DOC>
	<DOC>NCT00510146</DOC>
	<brief_summary>The purpose of this study is to assess whether olanzapine is superior to placebo in patients with bipolar depression.</brief_summary>
	<brief_title>Olanzapine Treatment of Patients With Bipolar I Disorder</brief_title>
	<detailed_description>1. Dose range and administration mode: Oral Olanzapine 5mg - 20mg/day 2. Duration: 1. Screening phase is 2-28 days. 2. Double-blind treatment phase is 6 weeks 3. Open-label extension phase is 18 weeks</detailed_description>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Each patient must be reliable, have a level of understanding sufficient to perform all tests and examinations required by the protocol, and must understand the nature of the study and have provided informed consent All female patients must test negative for pregnancy and females of breastfeeding potential must agree not to breastfeed an infant during the study and for 1 month following the last dose of study drug Patients must fulfill the criteria for a major depressive episode according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSMIVTR) as well as criteria for bipolar I disorder, depressed, as defined in the DSMIVTR, based on clinical assessment and confirmed by the structured diagnostic interview, the Mini International Neuropsychiatric Interview (MINI), at study entry Patients must have a current 17item Hamilton Depression Rating Scale (HAMD17) score greater than or equal to 18 at Visit 1 and Visit 2 Patients must have a current Young Mania Rating Scale (YMRS) total score less than or equal to 8 at Visit 2. Has received treatment within the past 30 days with a drug (not including study drug) that has not received regulatory approval for any indication at the time of study entry Has participated in a clinical trial of another investigational drug, including olanzapine, within 1 month (30 days) before study entry Was previously treated with olanzapine and had bipolar depression considered to be treatmentresistant to olanzapine or to olanzapine in combination with an available selective serotonin reuptake inhibitor (SSRI) Is experiencing (at the time of study entry) a current episode of bipolar depression that is greater than 90 days in duration Has been treatmentresistant to any therapy prescribed for bipolar depression when olanzapine alone or with an SSRI prescribed at an appropriate dose and duration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>